{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=30", "query": { "intervention": "Carbohydrate 50%", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 732, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T03:34:32.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01044693", "title": "Nebivolol in the Supine Hypertension of Autonomic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension", "Pure Autonomic Failure", "Multiple System Atrophy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Nebivolol 5 mg", "type": "DRUG" }, { "name": "metoprolol tartrate 50 mg", "type": "DRUG" }, { "name": "Sildenafil25 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2010-01", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2015-05-01", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01044693" }, { "nct_id": "NCT00118209", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Large B Cell Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 524, "start_date": "2005-05", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 47, "location_summary": "La Jolla, California • Mountain View, California • Palo Alto, California + 38 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St. Helena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118209" }, { "nct_id": "NCT00981799", "title": "Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed T-Cell Acute Lymphoblastic Leukemia", "Relapsed T-Cell Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Nelarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 23, "start_date": "2010-06", "completion_date": "2016-07-18", "has_results": true, "last_update_posted_date": "2020-10-01", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 26, "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00981799" }, { "nct_id": "NCT01086475", "title": "D-Cycloserine and Social Skills Training in Autism Spectrum Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Autistic Disorder", "Asperger's Disorder", "Pervasive Developmental Disorder NOS" ], "interventions": [ { "name": "D-cycloserine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 68, "start_date": "2010-03", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Cincinnati, Ohio", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01086475" }, { "nct_id": "NCT00693719", "title": "Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 31, "start_date": "2007-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693719" }, { "nct_id": "NCT00092222", "title": "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder", "HHV-8", "Malignancy", "HIV" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Observation Only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-10-28", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092222" }, { "nct_id": "NCT00350337", "title": "Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dengue" ], "interventions": [ { "name": "Pre-transfection F17", "type": "BIOLOGICAL" }, { "name": "Post-transfection F17", "type": "BIOLOGICAL" }, { "name": "Post-transfection F19", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 86, "start_date": "2006-04-05", "completion_date": "2008-03-13", "has_results": true, "last_update_posted_date": "2021-02-12", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350337" }, { "nct_id": "NCT06101745", "title": "Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Injury of Ureter During Surgery (Disorder)" ], "interventions": [ { "name": "Nizaracianine Triflutate", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Curadel Surgical Innovations, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2024-06-28", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 5, "location_summary": "Los Angeles, California • Redwood City, California • Orlando, Florida + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06101745" }, { "nct_id": "NCT04790903", "title": "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-07-02", "completion_date": "2024-05-21", "has_results": false, "last_update_posted_date": "2024-07-11", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 3, "location_summary": "New York, New York • Nashville, Tennessee", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04790903" }, { "nct_id": "NCT04092270", "title": "A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Endometrial High Grade Endometrioid Adenocarcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma", "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Peposertib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 55, "start_date": "2020-05-07", "completion_date": "2027-06-08", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-16T03:34:32.509Z", "location_count": 11, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092270" } ] }